Universiteit
Leiden
The Netherlands

Novel methods to expedite schistosome development

Koopman, J.P.R.

Citation
Koopman, J. P. R. (2026, January 29). *Novel methods to expedite schistosome development*. Retrieved from https://hdl.handle.net/1887/4290057

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/4290057

Note: To cite this publication please use the final published version (if applicable).



Appendices

Nederlandse samenvatting

Dankwoord (acknowledgements)

Curriculum Vitae

PhD Portfolio

List of publications

DANKWOORD (ACKNOWLEDGEMENTS)

Allereerst wil ik mijn dank uitspreken naar de studiedeelnemers zonder wie dit proefschrift nooit tot stand zou zijn gekomen.

Meta, bedankt voor je begeleiding tijdens het gehele traject. Het is werkelijk inspirerend om te zien hoe jij je met hart en ziel inzet om armoede-gerelateerde ziekten te bestrijden en het maakt me daarom ook trots om in jouw team te hebben mogen werken.

Alison, I'm very grateful that this PhD involved working with you and the amazing team in Uganda. Thank you for your hospitality and guidance along the way.

Jacqueline, jouw aandeel in deze PhD is enorm en het was zonder jou nooit gelukt. Onze prachtige samenwerking koester ik en het verheugt me daarom dat je mijn paranimf bent.

Eveline, een PhD kent hoge pieken en diepe dalen. Bedankt dat je er altijd voor me was als luisterend oor en nu ook mijn paranimf wilt zijn.

Emma, thank you for contributing your immunological expertise to elevate these projects. It has been a joy to work together.

Marie-Astrid, wat mooi dat we aan het einde van deze PhD net zoals aan het begin weer nauw samenwerken – ik waardeer je scherpe blik en gedrevenheid.

Maria, dat één ontmoeting zou leiden tot een wetenschapsstage, een epidemiologie master en een PhD in de parasitologie… Bedankt dat je me kansen hebt gegeven om mezelf verder academisch te ontwikkelen.

Ron, dank dat je me met kritische vragen scherp hebt gehouden in al onze gesprekken.

Dear schisto team, Jeroen, Miriam, Angela, Stan, Claudia thank you for all your hard work and dedication to produce cercariae and measure CAA. Although each production run was nerve-racking, I never doubted that together we could deliver and get those cercariae ready for infection, nor that we could get those CAA levels, even late in the evening.

Other schisto-aficionados, Eric, Lisette, Govert, Paul, Linda, Anna, Pytsje, Eva thank you for being so supportive of the CHI-S work and all your input interpreting the study findings.

To my Ugandan colleagues, Emmanuella, Moses, it has been wonderful to team up on CHI-S and thoroughly enjoyed the many meetings, conferences, and chats we shared together.

Klinische schisto team, Olivia, Geert, Vincent, Marijke, bedankt voor jullie hulp met de uitvoer van de studies en het verwerken van de vele samples. Dames van de vaccinatiepoli, Jos, Kitty, Gerdien, Petra, jullie inzet voor de studies is onmisbaar geweest. Bedankt voor jullie flexibiliteit, gezelligheid en goede zorgen.

J10-team, Pauline, Inge, Eileen, dank voor het in goede banen leiden van de productie van de cercariën.

LUCID colleagues, Yvonne, Erli, Abena, Rike, Dian, Farid, Roos, Laudine, Béatrice, Clarize, Chanel, Anne-Fleur, Laura, Lisanne, Johan, Maaike, and the many inspiring people I've shared offices with or met at the department: thank you for making these years dynamic and fun.

To my friends and family, thank you for keeping me grounded and showing me the importance of balance in life.

Theo, thank you for your unwavering support. I'm glad to have you in my life.

Als laatste, wil ik mijn ouders bedanken die me altijd hebben gestimuleerd om verder te kijken dan wat je kent of weet.

CURRICULUM VITAE

Jan Pieter Koopman was born in Bergen op Zoom, The Netherlands, on the 3rd of February 1992 and grew up in Zeeland. He attended a bilingual Dutch-English secondary school in Bergen op Zoom, before studying medicine at Leiden University in 2010. During his second year in medical school, he developed an interest in infectious diseases and started a research internship in the department of Infectious Diseases at Leiden University Medical Center (LUMC) examining genetic risk factors for urinary tract infections. In parallel, he took a half minor in Spanish language and culture and spent several months learning Mandarin in Shanghai and Taipei. For his extracurricular activities, he was awarded a Leiden University Honours College certificate in Medicine. During his clinical rotations, he travelled to Cape Town, South Africa where he was a medical elective in infectious diseases and emergency medicine at Tygerberg hospital. His scientific research internship was spent in Makassar, Indonesia where he investigated intestinal permeability and helminth infections in children from high vs low socioeconomic backgrounds, under supervision of dr. Firdaus Hamid (Hasanuddin University), dr. Erliyani Sartono (LUMC), and prof. Maria Yazdanbakhsh (LUMC).

Soon after receiving his medical degree in February 2018, he started working as a trial physician at the LUMC on several controlled human infection studies led by prof. Meta Roestenberg. He left the LUMC in September 2018 for an MSc degree in Epidemiology at the London School of Hygiene and Tropical Medicine, which he passed with merit. He returned to the LUMC in October 2019 to start his PhD project that focussed on controlled human *Schistosoma* infections to expedite vaccine development with prof. Meta Roestenberg. During his PhD, he was involved in several other studies, such as on rabies vaccination and controlled human hookworm infections, and regularly taught medical and biomedical students. In addition, he followed the Epidemiologist B training program at the department of Clinical Epidemiology, supervised by prof. Rolf Groenwold, which included a one-year secondment and advanced courses on epidemiological methods.

In 2024, he started working as clinician (ANIOS) in Internal Medicine at Haaglanden Medical Center in The Hague. Late 2025, he returned to the Leiden University Centre for Infectious diseases (LUCID) at LUMC as ANIOS for the post-COVID expertise centre.

PHD PORTFOLIO

PhD Training	Year
Courses	
Teach the teachers	2021
Analysis of repeated measurements	2021
Survival analysis	2022
Capita Selecta (epidemiology)	2022-2023
Prediction modelling and intervention research	2022
Skills for the practising epidemiologist	2023
Meta analysis	*2023*
Causal inference	2023
Laboratory Diagnosis of Human Parasitic Infections	2024
Congress attendance and poster or oral presentation	
Wellcome Trust human infection networking meeting	2020
IABS 3rd Human Challenge Trials in Vaccine Development	2020
Oral presentation at BSP	2021
Oral and poster presentation at AIGHD Masterclass: "Future of Vaccination"	2021
Poster at ASTMH	2021
Invited speaker at BSP	2022
Wellcome Trust meeting: use and utility of human infection study data	2022
Invited speaker at ICOPA	2022
Invited speaker at HIC-VAC annual meeting	2022
Invited speaker at Uganda Schistosomiasis Symposium I	2023
Oral presentation at BSP	2023
Invited speaker at UK Clinical Vaccine Network	2023
Oral presentation at ASTMH	2023
Oral presentation at Leiden Vaccine Symposium	2023
Invited speaker at "Havensymposium"	2023
Invited speaker at "MMM+M Reizigersgeneeskunde"	2024
Invited speaker at LUMC Top Research Seminar Theme Infection	2024
Teaching activities	
Half-minor fieldwork in Indonesia	2019
Docent-coach (BSc medicine)	2020
Infection in health and disease (BSc medicine)	2020-2023
Pathogen-host interactions (MSc biomedical Sciences)	2020-2024
Co-supervising student research project (MSc medicine)	2021
Global health and immunity (BSc liberal arts and sciences)	2021-2024
Global health (BSc medicine)	2021-2022
Mechanism of disease 1 (BSc medicine)	2021, 2023
Infectious agents and immunity (BSc biomedical sciences)	2022-2023
Design and analysis of biomedical studies (BSc biomedical sciences)	2022
Practical research skills (MSc medicine)	2022
Academic and scientific training year 1 (BSc medicine)	2023
Methods and techniques for scientific research (BSc biomedical sciences)	2023
Critical Appraisal of a Topic (BSc medicine)	2023-2024
Honours college lecture series (BSc medicine)	2023
Parasitology (MSc infection biology and control, CERMEL)	2024
Awards and prizes	
NVP travel award (ICOPA, Copenhagen)	2022
BSP travel award (BSP Spring meeting, Edinburgh)	2023
Best oral presentation Leiden Vaccine Symposium	2023
Other	
Peer review for Vaccine, Parasites & Vector, and PLoS Neglected Tropical Diseases	

LIST OF PUBLICATIONS

*Contributed equally

1. Driciru E, **Koopman JPR**, Steenbergen S, Sonnet F, Stam KA, Bes-Roeleveld L, Iliopoulou E, Janse JJ, Sijtsma J, Nambuya I, Hilt ST, König M, Kruize Y, Casacuberta-Partal M, Egesa M, van Dam GJ, Corstjens PLAM, van Lieshout L, Mpairwe H, MacDonald AS, Yazdanbakhsh M, Elliott AM, Roestenberg M, Houlder EL. T cell responses in repeated controlled human schistosome infection compared to natural exposure. Nat Commun. 2025 Jul 24;16(1):6827. doi: 10.1038/s41467-025-62144-8.
2. Roozen GVT, van Schuijlenburg R, Hensen ADO, **Koopman JPR**, Lamers OAC, Geurten FJA, Sijtsma JC, Baalbergen E, Janse JJ, Chevalley-Maurel S, Naar CM, Bezemer S, Kroeze H, van de Stadt HJF, de Visser B, Meij P, Tihaya MS, Colstrup E, Iliopoulou E, de Bes-Roeleveld HM, Wessels E, van der Stoep MYEC, Janse CJ, Murugan R, Franke-Fayard BMD, Roestenberg M. Single immunization with genetically attenuated PfΔmei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03347-2.
3. **Koopman JPR**, Houlder EL, Janse JJ, Lamers OA, Roozen GV, Sijtsma JC, Casacuberta-Partal M, Hilt ST, van der Stoep MYEC, van Amerongen-Westra IM, Brienen EA, Wammes LJ, van Lieshout L, van Dam GJ, Corstjens PL, van Diepen A, Yazdanbakhsh M, Hokke CH, Roestenberg M. Clinical tolerance but no protective efficacy in a placebo-controlled trial of repeated controlled schistosome infection. J Clin Invest. 2024 Dec 12:e185422. doi: 10.1172/JCI185422.
4. Lamers OAC, Franke-Fayard BMD, **Koopman JPR**, Roozen GVT, Janse JJ, Chevalley-Maurel SC, Geurten FJA, de Bes-Roeleveld HM, Iliopoulou E, Colstrup E, Wessels E, van Gemert GJ, van de Vegte-Bolmer M, Graumans W, Stoter TR, Mordmüller BG, Houlder EL, Bousema T, Murugan R, McCall MBB, Janse CJ, Roestenberg M. Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite. N Engl J Med. 2024 Nov 21;391(20):1913-1923. doi: 10.1056/NEJMoa2313892
5. Overduin LA, **Koopman JPR**, Prins C, Verbeek-Menken PH, de Pijper CA, Heerink F, van Genderen PJJ, Grobusch MP, Visser LG. Rabies knowledge gaps and risk behaviour in Dutch travellers: An observational cohort study. Travel Med Infect Dis. 2024 Jul-Aug;60:102739. doi: 10.1016/j.tmaid.2024.102739.
6. Houlder EL, Stam KA, **Koopman JPR**, König MH, Langenberg MCC, Hoogerwerf MA, Niewold P, Sonnet F, Janse JJ, Partal MC, Sijtsma JC, de Bes-Roeleveld LHM, Kruize YCM, Yazdanbakhsh M, Roestenberg M. Early symptom-associated inflammatory responses shift to type 2 responses in controlled human schistosome infection. Sci Immunol. 2024 Jul 5;9(97):eadl1965. doi: 10.1126/sciimmunol.adl1965.
7. Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, **Koopman JPR**, Lamers OAC, Kuijer M, Myeni SK, Binnendijk RSV, den Hartog G, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose. Clin Microbiol Infect. 2024 Mar 27:S1198-743X(24)00159-9. doi: 10.1016/j.cmi.2024.03.028.

8. Prins MLM, Roozen GVT, Pothast CR, Huisman W, van Binnendijk R, den Hartog G, Kuiper VP, Prins C, Janse JJ, Lamers OAC, **Koopman JPR**, Kruithof AC, Kamerling IMC, Dijkland RC, de Kroon AC, Azimi S, Feltkamp MCW, Kuijer M, Jochems SP, Heemskerk MHM, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial. NPJ Vaccines. 2024 Jan 2;9(1):1. doi: 10.1038/s41541-023-00785-w.

9. Hoogerwerf MA, Janse JJ, Kuiper VP, van Schuijlenburg R, Kruize YC, Sijtsma JC, Nosoh BA, **Koopman JPR**, Verbeek-Menken PH, Westra IM, Meij P, Brienen EA, Visser LG, van Lieshout L, Jochems SP, Yazdanbakhsh M, Roestenberg M. Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial. Lancet Microbe. 2023 Dec;4(12):e1024-e1034. doi: 10.1016/S2666-5247(23)00218-5.

10. Barnes MVC, Mandla A, Smith E, Maskuniitty M, Openshaw PJM; **HIC-Vac meeting contributors**. Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022. Immunother Adv. 2023 Oct 31;3(1):ltad024. doi: 10.1093/immadv/ltad024.

11. **Koopman JPR,** Houlder EL, Janse JJ, Casacuberta-Partal M, Lamers OAC, Sijtsma JC, de Dood C, Hilt ST, Ozir-Fazalalikhan A, Kuiper VP, Roozen GVT, de Bes-Roeleveld LM, Kruize YCM, Wammes LJ, Smits HH, van Lieshout L, van Dam GJ, van Amerongen-Westra IM, Meij P, Corstjens PLAM, Jochems SP, van Diepen A, Yazdanbakhsh M, Hokke CH, Roestenberg M. Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection study. EBioMedicine. 2023 Oct 12;97:104832. doi: 10.1016/j.ebiom.2023.104832.

12. **Koopman JPR*,** Overduin LA*, Prins C, Verbeek-Menken PH, De Pijper CA, Eblé PL, Heerink F, van Genderen PJJ, Grobusch MP, Visser LG. Boostability after single-visit pre-exposure prophylaxis with rabies vaccine: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2023 Oct 3:S1473-3099(23)00452-8. doi: 10.1016/S1473-3099(23)00452-8.

13. Abaasa A, Egesa M, Driciru E, **Koopman JPR,** Kiyemba R, Sanya RE, Nassuuna J, Ssali A, Kimbugwe G, Wajja A, van Dam GJ, Corstjens PLAM, Cose S, Seeley J, Kamuya D, Webb EL, Yazdanbakhsh M, Kaleebu P, Siddiqui AA, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial. Immunother Adv. 2023 Jul 20;3(1):ltad010. doi: 10.1093/immadv/ltad010.

14. van der Plas JL, Kuiper VP, Bagchus WM, Bödding M, Yalkinoglu Ö, Tappert A, Seitzinger A, Spangenberg T, Bezuidenhout D, Wilkins J, Oeuvray C, Dhingra SK, Thathy V, Fidock DA, Smidt LCA, Roozen GVT, **Koopman JPR,** Lamers OAC, Sijtsma J, van Schuijlenburg R, Wessels E, Meij P, Kamerling IMC, Roestenberg M, Khandelwal A. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. Lancet Infect Dis. 2023 Jul 3:S1473-3099(23)00212-8. doi: 10.1016/S1473-3099(23)00212-8.

15. Egesa M, Kiberu D, Sanya RE, Alabi A, Sonnet F, **Koopman JPR**, Baluku JB, Oguttu DW, Driciru E, Odongo M, Walusimbi B, Elliott AM, Nkurunungi G. Uganda Schistosomiasis Symposium 2023: understanding morbidity drivers and developing controlled human infection models for vaccine research. Trends Parasitol. 2023 Apr 6:S1471-4922(23)00091-0. doi: 10.1016/j.pt.2023.03.017.

16. Houlder EL, Costain AH, Nambuya I, Brown SL, **Koopman JPR**, Langenberg MCC, Janse JJ, Hoogerwerf MA, Ridley AJL, Forde-Thomas JE, Colombo SAP, Winkel BMF, Galdon AA, Hoffmann KF, Cook PC, Roestenberg M, Mpairwe H, MacDonald AS. Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis. Nat Commun. 2023 Apr 3;14(1):1863. doi: 10.1038/s41467-023-37502-z.

17. Kuiper VP, van der Plas P, Hoogerwerf MA, **Koopman JPR**, van der Meulen AE, Roukens AHE, Visser LG, Roestenberg M. A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease. Vaccine. 2022 Oct 12;40(43):6201-6205. doi: 10.1016/j.vaccine.2022.09.006.

18. **Koopman JPR*,** Amaruddin AI*, Muhammad M, Lenaerts K, van Eijk HMH, Brienen EAT, Geelen AR, van Lieshout L, Wahyuni S, Kuijper EJ, Zwittink RD, Hamid F, Sartono E, Yazdanbakhsh M. Intestinal permeability before and after albendazole treatment in low and high socioeconomic status schoolchildren in Makassar, Indonesia. Sci Rep. 2022 Mar 1;12(1):3394. doi: 10.1038/s41598-022-07086-7.

19. Casacuberta-Partal M, van Lieshout L, van Diepen A, Sijtsma J, Ozir-Fazalalikhan A, **Koopman JPR**, de Dood CJ, Corstjens PLAM, van Dam GJ, Hokke CH, Roestenberg M. Excretion patterns of *Schistosoma mansoni* antigens CCA and CAA by adult male and female worms, using a mouse model and ex vivo parasite cultures. Parasitology. 2021 Nov 5:1-27. doi: 10.1017/S0031182021001839.

20. **Koopman JPR,** Lule SA, Zziwa C, Akurut H, Lubyayi L, Nampijja M, Akello F, Balungi P, Tumusiime J, Oduru G, Elliott AM, Webb EL, Bradley J. The determinants of lipid profiles in early adolescence in a Ugandan birth cohort. Sci Rep. 2021 Aug 13;11(1):16503. doi: 10.1038/s41598-021-96035-x.

21. **Koopman JPR,** Kuiper VP, Hoogerwerf MA. Gecontroleerde humane infectiestudies [Controlled human infection studies: efficient research on tropical infectious diseases]. Ned Tijdschr Geneeskd. 2021 Jul 16;165:D5717.

22. **Koopman JPR,** Driciru E, Roestenberg M. Controlled human infection models to evaluate schistosomiasis and hookworm vaccines: where are we now? Expert Rev Vaccines. 2021 Jul 6. doi: 10.1080/14760584.2021.1951244.

23. Amaruddin AI, **Koopman JPR**, Muhammad M, et al. Bee- and Wasp-Venom Sensitization in Schoolchildren of High- and Low-Socioeconomic Status Living in an Urban Area of Indonesia. Int Arch Allergy Immunol. 2021;1-10. doi:10.1159/000516155.

24. Driciru E, **Koopman JPR**, Cose S, Siddiqui AA, Yazdanbakhsh M, Elliott AM, Roestenberg M. Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings. Front Immunol. 2021 Mar 4;12:635985. doi: 10.3389/fimmu.2021.635985.

25. Ducarmon QR, Hoogerwerf MA, Janse JJ, Geelen AR, **Koopman JPR,** Zwittink RD, Goeman JJ, Kuijper EJ, Roestenberg M. Dynamics of the bacterial gut microbiota during controlled human infection with Necator americanus larvae. Gut Microbes. 2020 Nov 9;12(1):1-15. doi: 10.1080/19490976.2020.1840764.

26. Wahyuni S, van Dorst MMAR, Amaruddin AI, Muhammad M, Yazdanbakhsh M, Hamid F, **Koopman JPR**, Sartono E. The relationship between malnutrition and TH 2 immune markers: a study in school-aged children of different socio-economic backgrounds in Makassar, Indonesia. Trop Med Int Health. 2020 Nov 8. doi: 10.1111/tmi.13513.

27. Hoogerwerf MA, **Koopman JPR**, Janse JJ, Langenberg MCC, van Schuijlenburg R, Kruize YCM, Brienen EAT, Manurung MD, Verbeek-Menken P, van der Beek MT, Westra IM, Meij P, Visser LG, van Lieshout L, de Vlas SJ, Yazdanbakhsh M, Coffeng LE, Roestenberg M. A randomized controlled trial to investigate safety and variability of egg excretion after repeated controlled human hookworm infection. J Infect Dis. 2020 Jul 10:jiaa414. doi: 10.1093/infdis/jiaa414.

28. Amaruddin AI, Hamid F, **Koopman JPR**, Muhammad M, Brienen EA, van Lieshout L, Geelen AR, Wahyuni S, Kuijper EJ, Sartono E, Yazdanbakhsh M, Zwittink RD. The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia. Microorganisms. 2020 Jun 26;8(6):E961. doi: 10.3390/microorganisms8060961.

29. Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, Manurung M, Yap XZ, García AF, **Koopman JPR,** Meij P, Wessels E, Teelen K, van Waardenburg YM, van de Vegte-Bolmer M, van Gemert GJ, Visser LG, van der Ven AJAM, de Mast Q, Natasha KC, Abebe Y, Murshedkar T, Billingsley PF, Richie TL, Sim BKL, Janse CJ, Hoffman SL, Khan SM, Sauerwein RW. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020 May 20;12(544):eaaz5629. doi: 10.1126/scitranslmed.aaz5629.

30. Langenberg MCC, Hoogerwerf MA*, **Koopman JPR***, Janse JJ, Kos-van Oosterhoud J, Feijt C, Jochems SP, de Dood CJ, van Schuijlenburg R, Ozir-Fazalalikhan A, Manurung MD, Sartono E, van der Beek MT, Winkel BMF, Verbeek-Menken PH, Stam KA, van Leeuwen FWB, Meij P, van Diepen A, van Lieshout L, van Dam GJ, Corstjens PLAM, Hokke CH, Yazdanbakhsh M, Visser LG, Roestenberg M. A controlled human *Schistosoma mansoni* infection model to advance novel drugs, vaccines and diagnostics. Nat Med. 2020 Mar;26(3):326-332. doi: 10.1038/s41591-020-0759-x.

31. **Koopman JP**, Egesa M, Wajja A, Adriko M, Nassuuna J, Nkurunungi G, Driciru E, van Willigen G, Cose S, Yazdanbakhsh M, Kaleebu P, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Risk assessment for the implementation of controlled human *Schistosoma mansoni* infection trials in Uganda. AAS Open Res. 2019 Aug 13;2:17. doi: 10.12688/aasopenres.12972.2.

32. **Koopman JPR**, Hoogerwerf MA, Roestenberg M. Gecontroleerde humane infectiestudies. Tijdschrift voor Infectieziekten 2019;14;173-9.

33. Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens PLAM, Roestenberg M; **CoHSI clinical trial team.** Katayama Syndrome Without Schistosoma mansoni Eggs. Ann Intern Med. 2019 May 21;170(10):732-733. doi: 10.7326/L18-0438. Epub 2019 Jan 8.

34. van der Starre WE, van Nieuwkoop C, Thomson U, Zijderveld-Voshart MS, **Koopman JP**, van der Reijden TJ, van Dissel JT, van de Vosse E. Urinary proteins, vitamin D and genetic polymorphisms as risk factors for febrile urinary tract infection and relation with bacteremia: a case control study. PLoS One. 2015 Mar 25;10(3):e0121302. doi: 10.1371/journal.pone.0121302.